Next-Generation Sequencing Market by Product Type (Consumables, Platforms, Bioinformatics), Technology (SBS, Nanopore), Workflow (Sequencing, Data Analysis), Services, Application (Drug Discovery, Diagnostic, Agriculture) - Global Forecast to 2030

The next-generation sequencing market is expected to reach USD 29.53 billion in 2030, up from USD 14.94 billion in 2025, at a CAGR of 14.6% during the forecast period. The growing application of NGS in oncology, infectious diseases, reproductive health, metagenomics, and personalized medicine is the primary driver of market expansion. Meanwhile, advanced bioinformatics tools for data analysis and interpretation are facilitating the use of NGS, thereby helping a wider user base adopt the technique.

“Consumables accounted for the largest share of the product segment in the NGS market in 2024.”

The NGS products market is segmented into consumables, platforms, and bioinformatics tools. In 2024, consumables held the largest share. This segment includes reagents, library preparation kits, sequencing flow cells, and sample preparation kits, which are used in high volumes across many applications. Demand remains robust because consumables are purchased repeatedly, unlike instruments, which are generally one-time investments. The growing use of targeted sequencing and custom panels is also driving demand for specialized, application-specific consumables. Furthermore, an expanding user base and ongoing improvements in sequencing chemistries are drawing more customers toward consumables to simplify their workflows and improve data quality.

“The academic & research institutes segment accounted for the largest share by services end-user segment in the next-generation sequencing market in 2024.”

The next-generation sequencing services market is segmented by end user into academic & research institutes, pharmaceutical & biotechnology companies, hospitals & clinical laboratories, and other users. In 2024, academic and research institutes held the largest share. This leadership is supported by strong government and private funding for research programs, enabling higher spending on NGS-related needs, including instruments and consumables. Pharmaceutical and biotechnology companies represented the second-largest end-user segment in the market.

“The Asia Pacific region will grow at the highest CAGR from 2025 to 2030.”

The Asia Pacific region is estimated to be the fastest-growing segment of the market, owing to large-scale population genomics projects and rising demand for precision medicines. Additionally, the rising prevalence of rare and genetic diseases is attributed to the aging populations in countries such as Japan and China. These factors are supporting the adoption of sequencing technologies in healthcare management and treatment, driving market growth.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side- 70% and Demand Side 30%
• By Designation: Managers - 45% CXOs and Director-level - 30%, and Executives - 25%,
• By Region: North America -40%, Europe -25%, Asia-Pacific -25%, Latin America -5%, and Middle East -5%.

List of Companies Profiled in the Report:

• Illumina, Inc. (US)
• Thermo Fisher Scientific Inc. (US)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Danaher Corporation (US)
• QIAGEN (Netherlands)
• Agilent Technologies, Inc. (US)
• Revvity (US)
• Eurofins Scientific (Luxembourg)
• PacBio (US)
• Oxford Nanopore Technologies plc. (UK)
• Takara Bio Inc. (Japan)
• BGI Group (China)
• Merck KGaA (Germany)
• BD (US)
• 10X Genomics (US)
• New England Biolabs (US)
• Promega Corporation (US)
• Novogene Co., Ltd. (China)
• LGC Limited (UK)
• WuXi Biologics (China)
• MGI Tech Co. Ltd. (China)
• Tecan Trading AG (Switzerland)
• Twist Biosciences (US)
• Azenta US, Inc. (US)
• GenScript (US)
• SD Biosensor, Inc. (South Korea)
• Fulgent Genetics (US)
• Hamilton Company (US)
• Zymo Research Corporation (US)
• NeoGenomics Laboratories (US)
• Psomagen (US)

Research Coverage:

The scope of the report covers detailed information on the major factors, such as drivers, challenges, opportunities, and restraints, that influence the growth of the NGS market. A detailed analysis of key industry players has been conducted to provide insights into their business overview, product and service portfolio, key strategies such as product and service launches, collaborations, partnerships, expansions, agreements, and recent developments associated with the NGS market. Competitive analysis of top players and upcoming startups in the NGS market ecosystem is also covered in this report.

Key Benefits of Buying the Report:

The report will help market leaders and new entrants by providing the closest approximations of revenue for the overall NGS market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain insights to better position their business and develop suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights into the following points:

Analysis of key drivers (advancements in sequencing platforms, rising clinical applications of sequencing, growing demand for precision medicine, declining sequencing costs), restraints (complex data analysis, high initial capital investment), opportunities (integration of AI and ML, adoption of long-read sequencing technologies, emphasis on multiomics integration), and challenges (standardization issues) influencing the growth of the market.

• Product Development/Innovation: Detailed insights on newly launched products/services of the next-generation sequencing market
• Market Development: Comprehensive information about lucrative markets - the report analyzes the market across varied regions
• Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the next-generation sequencing market
• Competitive Assessment: Illumina, Inc. (US), Thermo Fisher Scientific Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Danaher Corporation (US), QIAGEN (Netherlands), Agilent Technologies, Inc. (US), Revvity (US), Eurofins Scientific (Luxembourg), PacBio (US), Oxford Nanopore Technologies plc. (UK), Takara Bio Inc. (Japan), BGI Group (China), Merck KGaA (Germany), BD (US), 10X Genomics (US), New England Biolabs (US), Promega Corporation (US), Novogene Co., Ltd. (China), LGC Limited (UK), WuXi Biologics (China), MGI Tech Co. Ltd. (China), Tecan Trading AG (Switzerland), Twist Biosciences (US), Azenta US, Inc. (US), GenScript (US), SD Biosensor, Inc. (South Korea), Fulgent Genetics (US), Hamilton Company (US), Zymo Research Corporation (US), NeoGenomics Laboratories (US), and Psomagen (US)

Show more